Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
VBCC Perspectives
The ASCO Value Framework: To What End?
ASCO’s Value Framework
,
Value-Based Care
,
VBCC Perspectives
,
Economics & Value
July 2015, Vol 6, No 6
Read Article
ASCO’s Value Framework Abandons the Hippocratic Oath
By
Robert Goldberg, PhD
ASCO’s Value Framework
,
Value-Based Care
,
VBCC Perspectives
,
Economics & Value
July 2015, Vol 6, No 6
The American Society of Clinical Oncology (ASCO) new value framework abandons the Hippocratic Oath. No longer is the doctor’s first obligation to “apply, for the benefit of the sick, all measures which are required.” Instead, ASCO’s value framework has the potential to help insurers “evaluate the relative value of new treatments” as they develop “benefit structures, adjustment of insurance premiums, and implementation of clinical pathways and administrative controls."
Read Article
Logistic Toxicity: Obstacles to the Efficient Delivery of Cancer Care
By
Barry D. Brooks, MD
Value-Based Care
,
VBCC Perspectives
October 2014, Vol 5 , No 8
The Merriam-Webster dictionary defines “logistics” as the things that must be done to plan and organize a complicated activity that involves many people. The modern delivery of cancer care precisely parallels this definition.
Read Article
Promising New Therapies in the Breast Cancer Pipeline
By
Phoebe Starr
Value-Based Care
,
VBCC Perspectives
March 2014, Vol 5, No 2
San Antonio, TX—Many new drugs are currently in development for the treatment of patients with breast cancer. The following is a selection of drugs featured at the 2013 San Antonio Breast Cancer Symposium.
Read Article
Considering Prophylactic Salpingo-Oophorectomy in Women with BRCA Mutations
By
Jonathan S. Berek, MD, MMS
;
Allison W. Kurian, MD, MSc
Value-Based Care
,
VBCC Perspectives
March 2014, Vol 5, No 2
The study “Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation” that was recently published in the Journal of Clinical Oncology (Finch AP, et al. 2014 February 24 [Epub ahead of print]) provides an update of previous work by the same investigators on a similar population.
Read Article
Cancer Prehabilitation May Reduce Healthcare Costs and Improve Outcomes
By
Julie K. Silver, MD
Economics & Value
,
VBCC Perspectives
October 2013, Vol 4, No 8
Prehabilitation (or "prehab") has a long history as an important part of the rehabilitation care continuum.
Read Article
The Importance of Prioritizing Palliative Care in Oncology: How Payers Can Assist Providers
By
Rhonda Greenapple, MSPH, Reimbursement Intelligence
;
Ellen Licking
;
John Whang, MD, FACC,
Palliative Care
,
VBCC Perspectives
February 2013, Vol 4, No 2
Too often, palliative care, which was officially recognized as a medical specialty in 2006, is mistakenly thought to be synonymous with hospice care. Although palliative care includes the coordination of care for patients at the end of their lives, it more broadly aims to reduce patient suffering and is available to all patients with serious disease.
Read Article
A Call for Transparency in Drug Pricing
Value-Based Care
,
VBCC Perspectives
January 2013, Vol 4, No 1
In the December 2012 issue of
Value-Based Cancer Care
(
VBCC
), several Editorial Board members addressed the recent events surrounding the cost of cancer drugs and the reduction of the price of ziv-aflibercept (Zaltrap).
VBCC
continued this discussion with Al B. Benson III, MD, FACP, FASCO.
Read Article
How Will We Pay for Cancer Treatment?
By
Ted Okon, MBA
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
November 2012, Vol 3, No 8
With the fanfare of a New York Times Op-Ed piece by Peter B. Bach, MD, and colleagues, the announcement was made that Memorial Sloan-Kettering Cancer Center (MSKCC) would exclude the new colorectal cancer drug ziv-aflibercept (Zaltrap) from its formulary.
Read Article
Payers’ Support of Clinical Decisions Allows Providers to Choose Most Effective, Cost-Saving Therapies
By
Ira Klein, MD, MBA, FACP
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
November 2012, Vol 3, No 8
The cost of cancer care is staggering. Global sales of cancer drugs alone are forecast to grow at a rate of 12% to 15% annually, reaching $75 billion to $80 billion by the end of this year, according to IMS Health.
Read Article
Page 3 of 5
1
2
3
4
5
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma